# Exero Medical

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/exero-medical

- Industry: Medical Devices & Equipment
- Headquarters: Or Yehuda, Israel
- Website: www.exeromedical.com
- Total disclosed funding: $10M
- Latest round: Seed (Feb 13, 2025)
- Investors on record: 3

## About

Exero Medical is an innovative healthcare company focused on developing non-invasive technologies for early detection of gastrointestinal surgical complications, enhancing patient outcomes through advanced monitoring solutions.Founded in 2018 in Or Yehuda, Israel, Exero Medical specializes in early detection technologies for gastrointestinal surgery complications. The company has engaged in three significant deals, with its most recent funding round being a Seed round on February 13, 2025, raising USD 10.00 mn from investors including Edge Medical Ventures and Longevity Venture Partners. The founder's details and prior company history are not specified, indicating a focus on its current operational strategy without prior affiliations mentioned.Exero Medical's primary offering is the xBar System, a non-invasive technology designed for early detection of complications following gastrointestinal surgery, particularly anastomotic leaks. The xBar System aims to address the critical need for timely diagnosis and intervention, which can significantly reduce morbidity, mortality, and extended hospital stays associated with delayed leak presentations. The technology utilizes advanced monitoring capabilities to provide healthcare professionals with actionable insights, facilitating earlier interventions and improving patient outcomes. Exero Medical serves a diverse clientele, including hospitals, surgical centers, and healthcare providers focusing on gastrointestinal procedures. Currently, the xBar System is in the investigational phase and is limited to research settings in the United States while also being explored in international markets to establish its efficacy and reliability in various healthcare environments.Exero Medical operates within a framework that emphasizes partnerships and collaborations with healthcare institutions to support the clinical validation and potential commercialization of the xBar System. The company is backed by significant investments from various venture capital firms and healthcare organizations. Revenue generation primarily revolves around partnerships with hospitals and surgical centers that participate in clinical studies, where they provide access to the xBar System for investigational use. Specific pricing structures and revenue details remain proprietary, as the xBar System is not yet commercially available, with all activities currently focused on research and development rather than sales.In February 2025, Exero Medical raised USD 2.70 mn in grant funding, which will be utilized to complete its FDA pivotal trial, support regulatory clearance, and facilitate the launch of the xBar System in the U.S. market. The company focuses on expanding its presence in international markets by establishing partnerships that validate the technology's effectiveness, anticipating broader market entry following successful trials.

## Funding rounds

- Seed, Feb 13, 2025, $10M — Tech Council Ventures, Longevity Venture Partners, Edge Medical Ventures

## Investors

- Tech Council Ventures (https://capitalatlas.ai/funds/tech-council-ventures) — Seed
- Longevity Venture Partners (https://capitalatlas.ai/funds/longevity-venture-partners) — Seed
- Edge Medical Ventures (https://capitalatlas.ai/funds/edge-medical-ventures) — Seed